Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 10 of 10 for “"CTCL"”.
-
Immunological Mechanisms of Extracorporeal Photopheresis In Cutaneous T Cell Lymphoma and Graft Versus Host Disease
… for leukemic cutaneous T cell lymphoma (L-CTCL) and graft versus host disease (GVHD), but whether the mechanism(s) of action in these two diseases is (are) identical or different is unclear. To determine the effects of ECP <em>in vivo</em>, we studied regulatory T cells (T-regs), cytotoxic …
-
Charakterisierung von Tumorantigenen des kutanen T-Zell Lymphoms: Serologische Immunantwort und Expressionsanalyse
… sind, wurden für das kutane T-Zell Lymphom (CTCL) bislang nur sehr wenige tumorassoziierte Antigene identifiziert. Die Antigene se57-1, se70-2, cTAGE-1 und GBP-5ta wurden durch serologisches Durchsuchen einer Phagenbank aus Testis- bzw. Tumorgewebe (SEREX-Methode) identifiziert. In der …
-
Serologische Identifizierung von Tumorantigenen des kutanen T-Zell Lymphoms mit Fokus auf Plasmamembranproteine
… die spezifisch für die kutane T-Zell Lymphome (CTCL), Sézary Syndrom (SzS) und Mycosis fungoides (MF), sind. Zu ihrer Identifizierung wurde zunächst über differentielle Zentrifugation ein Oberflächenpräparat der CTCL-Zelllinie HuT78 hergestellt. Es diente als Antigengemisch für die Immunisierung …
-
A candidate gene based investigation of aberrant DNA methylation in the pathogenesis of primary cutaneous T-cell lymphoma
Primary cutaneous T-cell lymphoma (CTCL) is a clinically heterogeneous malignancy of mature skin-homing T-cells. Mycosis fungoides (MF) is an indo¬lent subtype of CTCL whilst Sezary syndrome (SS) is an aggressive leukaemic variant characterised by the presence of malignant Sezary cells in the …
-
A study of activation antigens involved in the pathologicalmechanisms and pathways of cutaneous malignant disease withparticular emphasis on cutaneous T cell lymphoma andmalignant melanoma
… The studies into cutaneous T cell lymphoma (CTCL) and malignant melanoma (MM), presented here involved predominantly immunocytochemical procedures and relate to the investigations into AP-1 protein expression in CTCL and melanocyte activation antigens in MM. Results: Findings indicate that …
-
Exploring the genetic landscape in cutaneous T-cell lymphoma with short- and long-read sequencing
… /> #### Abstract Cutaneous T-cell lymphoma (CTCL) are a group of diseases with heterogenous genetic alterations. In general, there are recurrent copy-number variants and rare, single nucleotide variants that ultimately cluster in a limited number of pathways, including JAK-STAT- and T-cell …
-
Identification of differentially expressed genes in AHI-1-mediated leukemic transformation in cutaneous t-cell lymphoma
… particularly in cutaneous T-cell lymphoma (CTCL) cell lines (Hut 78 and Hut 102). Hut 78 is derived from a patient with Sezary syndrome, a common leukemic variant of the human CTCL mycosis fungoides. Aberrant expression of AHI-1 mRNA and protein has been found in CD4⁺CD7⁻ leukemic Sezary …
-
Novel factors in the pathogenesis of cutaneous T cell lymphomas
… the pathogenesis of cutaneous T cell lymphomas (CTCL) and reveals potential new biomarkers and therapeutic targets to improve diagnostics. CTCLs are also known as a heterogeneous group of non-Hodgkin lymphomas. The clinical behavior of these lymphomas varies from benign forms of …
-
Ctla-4 transcriptional activation: regulation of induced expression
… Malignant cells of cutaneous T cell lymphoma (CTCL) express elevated levels of CTLA-4, which may contribute to reduced</p> <p>tumor immunity as the disease progresses. The objective of this work was to identify mechanisms of transcriptional regulation of CTLA-4 to better understand how this …
-
THE DEVELOPMENT OF SELECTIVE PHOTOSENSITIZERS TO TARGET PATHOGENIC T CELLS AND PREVENT GRAFT-VERSUS-HOST DISEASE
… T cells. In cutaneous T cell lymphoma (CTCL), malignant T cells migrate throughout the skin to mediate the disease. Consequently, developing new therapeutics to selectively target pathogenic and malignant T cells may improve clinical outcomes. In the work presented here, we have created …